Get the Stockscreener App
183.08
1.07%
1.94
After Hours:
183.75
0.67
+0.37%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $183.08, with a volume of 5.11M.
It is up +1.07% in the last 24 hours and down -2.54% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$181.14
Open:
$181.14
24h Volume:
5.11M
Relative Volume:
0.97
Market Cap:
$323.72B
Revenue:
$55.53B
Net Income/Loss:
$5.12B
P/E Ratio:
50.16
EPS:
3.65
Net Cash Flow:
$15.62B
1W Performance:
+9.13%
1M Performance:
-2.54%
6M Performance:
+16.57%
1Y Performance:
+31.63%
1-Day Range:
$180.89
$184.21
1-Week Range:
$166.92
$184.21
52-Week Range:
$137.65
$207.32
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
183.08 | 323.72B | 55.53B | 5.12B | 15.62B | 3.65 |
|
LLY
Lilly Eli Co
|
788.19 | 752.65B | 40.86B | 8.37B | -2.28B | 5.4193 |
|
NVO
Novo Nordisk Adr
|
106.13 | 471.56B | 39.36B | 13.79B | 9.83B | 2.4077 |
|
JNJ
Johnson Johnson
|
155.40 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
|
MRK
Merck Co Inc
|
103.12 | 260.72B | 63.17B | 12.15B | 14.84B | 1.80 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie (NYSE:ABBV) Stock Price Up 1.6%Should You Buy? - MarketBeat
CreativeOne Wealth LLC Increases Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Position Reduced by MetLife Investment Management LLC - MarketBeat
Bridgewater Associates LP Reduces Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Facial Injectables Industry May See a Big Move | Medytox, AbbVie, Sanofi - openPR
Biopharmaceuticals Market Forecasted for Major Expansion - openPR
Loomis Sayles & Co. L P Trims Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
People and Purpose: AbbVie's GC on Leading With Impact and Inspiring Change - Law.com
AbbVie (NYSE:ABBV) Trading 0.5% HigherTime to Buy? - MarketBeat
Shum Financial Group Inc. Buys Shares of 5,510 AbbVie Inc. (NYSE:ABBV) - MarketBeat
Principal Street Partners LLC Has $7.93 Million Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Purchased by Fmr LLC - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by D.A. Davidson & CO. - MarketBeat
Dai ichi Life Insurance Company Ltd Decreases Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
The Manufacturers Life Insurance Company Sells 29,310 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Navigating Market Uncertainty: Intrinsic Value of AbbVie Inc - GuruFocus.com
Is AbbVie Inc. (ABBV) the Best Dividend Aristocrat Stock To Buy Right Now? - Insider Monkey
AbbVie (NYSE:ABBV) Trading Up 1.4%Time to Buy? - MarketBeat
Despite Neuroscience Setback, AbbVie Has Strong Recovery Ahead (ABBV) - Seeking Alpha
AbbVie Inc. stock rises Monday, still underperforms market - MarketWatch
AbbVie Stock Rises After Leerink Partners Upgrades Its Rating - Barchart
AbbVie Inc. (NYSE:ABBV) Shares Acquired by Associated Banc Corp - MarketBeat
AbbVie to Present at Citi's 2024 Global Healthcare Conference - StockTitan
AbbVie Inc. (NYSE:ABBV) Shares Bought by Harvest Fund Management Co. Ltd - MarketBeat
Proton Pump Inhibitors Market to Surpass Valuation of USD 7.35 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
FY2026 EPS Estimates for AbbVie Lifted by Leerink Partnrs - MarketBeat
FY2024 Earnings Forecast for AbbVie Issued By Zacks Research - MarketBeat
Daiwa Securities Group Inc. Buys 21,329 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Summit Trail Advisors LLC Purchases 3,865 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Westfield Capital Management Co. LP Has $125.15 Million Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Alpha DNA Investment Management LLC Decreases Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Buys 2,838 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie (NYSE:ABBV) Shares Acquired Rep. Marjorie Taylor Greene - MarketBeat
Are Hedge Funds Betting Big On AbbVie Inc. (ABBV)? - Insider Monkey
AbbVie Inc. (NYSE:ABBV) Shares Bought by Cerity Partners LLC - MarketBeat
AbbVie (NYSE:ABBV) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
AbbVie upgraded to Outperform from Market Perform at Leerink - Yahoo Finance
Leerink Partners Upgrades AbbVie (ABBV) - MSN
Leerink Partners upgrades AbbVie shares to "Outperform" - TradingPedia
AbbVie Inc. (NYSE:ABBV) Receives $203.50 Consensus Target Price from Analysts - MarketBeat
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie gains on Leerink Partners upgrade to Outperform - Yahoo Finance
AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback - Yahoo! Voices
AbbVie: Upgrading to 'Strong Buy' After Pullback (NYSE:ABBV) - Seeking Alpha
AbbVie (NYSE:ABBV) Trading Up 2.9%Here's Why - MarketBeat
AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback - MSN
One Veteran's Journey with Depression and AbbVie's Commitment to Mental Health Research - AbbVie
AbbVie, Nvidia Lead Friday's Market Cap Stock Movers - Investing.com
AbbVie, Nvidia Lead Friday's Market Cap Stock Movers By Investing.com - Investing.com Australia
AbbVie Inc. (NYSE:ABBV) Shares Purchased by Nwam LLC - MarketBeat
Zacks Research Weighs in on AbbVie's Q1 Earnings (NYSE:ABBV) - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):